The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors

Journal of Nuclear Medicine

Volumn 45, Issue 1, 2004, Pages 17-21

  Gayed, Isis ^a,b   Vu, Thuan ^a   Iyer, Revathy ^a   Johnson, Marcella ^a   Macapinlac, Homer ^a   Swanston, Nancy ^a   Podoloff, Donald ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Department of Nuclear Medicine ^*  (United States)

Author keywords

Gastrointestinal stromal tumors; Imatinib mesylate; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; DIAGNOSTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL TUMOR; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR VOLUME; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFECT; LABORATORY DIAGNOSIS; METASTASIS; METHODOLOGY; MIDDLE AGED; PROGNOSIS; RADIOGRAPHY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STATISTICS; STROMA CELL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PIPERAZINES; PROGNOSIS; PYRIMIDINES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS; STROMAL CELLS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 1842451619     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Burkill GJ, Badran M, Al-Muderis O, et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology. 2003;226:527-532.
2. Nishida T, Kumano S, Sugiura T, et al. Multidetector CT of high-risk patients with occult gastrointestinal stromal tumors. AJR. 2003;180:185-189.
3. Demetri G. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer. 2002;38(suppl 5):S52-S59.
4. Casper ES. Gastrointestinal stromal tumors. Curr Treat Options Oncol. 2000;1:267-273.
5. Dematteo RP, Maki RG, Antonescu C, Brennan MF. Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. Curr Probl Surg. 2003;40:144-193.
6. Muler JH, Baker L, Zalupski MM. Gastrointestinal stromal tumors: chemotherapy and imatinib. Curr Oncol Rep. 2002;4:499-503.
7. Plager C, Papadopoulos NE, Salem P, Benjamin RS. Adriamycin-based chemotherapy for leiomyosarcoma of the stomach and small intestine [abstract]. Proceedings of the American Society of Clinical Oncology. Alexandria, VA; American Society of Clinical Oncology; 1991.
8. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol. 2000;7:705-712.
9. Hurlimann J, Gardiol D. Gastrointestinal stromal tumours: an immunohistochemical study of 165 cases. Histopathology. 1991;19:311-320.
10. Walker P, Dvorak AM. Gastrointestinal autonomic nerve (GAN) tumor. Ultrastructural evidence for a newly recognized entity. Arch Pathol Lab Med. 1986;110:309-316.
11. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998;11:728-734.
12. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of C-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
13. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-1056.
14. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of C-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932.
15. Tuveson DA, Willis NA, Jacks T, Griffin JD, et al. STI571 inactivation of the gastrointestinal stromal tumor C-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20:5054-5058.
16. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002;38(suppl 5):S60-S65.
17. Van den Abbeele AD. F18-FDG-PET provides early evidence of biological response to STI571 in patients with malignant gastrointestinal stromal tumors (GIST) [abstract]. Proceedings of the American Society of Clinical Oncology. Alexandria, VA; American Society of Clinical Oncology; 2001.
18. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-1782.
19. Heges L, Olkin I. Statistical Methods for Meta-Analysis. San Diego, CA: Academic Press Inc; 1985.
20. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet. 2001;358:1421-1423.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
22. Chen MY, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). AJR. 2002;179:1059-1062.
23. Choi H, Faria SC, Benjamin RS, Podoloff DA, Macapinlac HA, Charnsangavej C. Monitoring treatment effects of STI-571 on gastrointestinal stromal tumors (GIST) with CT and PET: a quantitative analysis [abstract]. Radiology. 2002;225:P583.